We sought to evaluate whether differences in rates of contraceptive discontinuation exist among black and white women receiving contraceptive counseling and no-cost contraception among users of long-acting reversible contraceptive (LARC; intrauterine devices or subdermal implant) and non-LARC (oral contraceptive pills, contraceptive vaginal ring, patch, or injection) methods.
Materials and
Methods: We analyzed data from a prospective cohort study of 7546 non-Hispanic black and white women who participated in the Contraceptive CHOICE Project. Among women who initiated their method within 12 weeks of enrollment, discontinuation was defined as any break in use longer than 1 month. Using Cox proportional hazards regression analysis, we estimated discontinuation stratified by use of LARC methods.
Results:
There were no statistically significant differences in contraceptive discontinuation between black and white women at 12, 24, or 36 months among both LARC [12-month adjusted hazard ratio (HRadj-12M) 1.01 (95% confidence interval or 95% CI 0.86–1.18); HRadj-24M 1.10 (95% CI 0.97–1.24); and HRadj-36M 1.10 (95% CI 0.98–1.23)] and non-LARC users [HRadj-12M 1.08 (95% CI 0.92, 1.26); HRadj-24M 1.07 (95% CI 0.94, 1.23); and HRadj-36M 1.08 (95% CI 0.95, 1.23)] adjusting for confounders. Secondary analyses found no significant differences in discontinuation of LARC and non-LARC methods among black and white women at highest risk of pregnancy or those receiving public assistance at baseline.
Conclusions:
At 12, 24, and 36 months there were no differences in contraceptive discontinuation of both LARC methods and non-LARC methods when comparing white and black women.
Get full access to this article
View all access options for this article.
References
1.
The Best Intentions. Unintended pregnancy and the well-being of children and families. Washington, DC: The Best Intentions, 1995.
2.
TrussellJ. The cost of unintended pregnancy in the United States. Contraception, 2007; 75:168–170.
3.
SawhillIV, KarpilowQ, VenatorJ. The impact of unintended childbearing on future generations. Washington, DC: Brookings Institution, 2014.
4.
HenshawSK. Unintended pregnancy in the United States. Fam Plann Perspect, 1998; 30:24–29, 46.
5.
FinerLB, HenshawSK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health, 2006; 38:90–96.
6.
FinerLB, ZolnaMR. Declines in unintended pregnancy in the United States, 2008–2011. N Engl J Med, 2016; 374:843–852.
7.
FinerLB, ZolnaMR. Unintended pregnancy in the United States: Incidence and disparities, 2006. Contraception, 2011; 84:478–485.
8.
WinnerB, PeipertJF, ZhaoQ, et al.Effectiveness of long-acting reversible contraception. N Engl J Med, 2012; 366:1998–2007.
9.
TrussellJ, HenryN, HassanF, PreziosoA, LawA, FilonenkoA. Burden of unintended pregnancy in the United States: Potential savings with increased use of long-acting reversible contraception. Contraception, 2013; 87:154–161.
10.
ShihG, VittinghoffE, SteinauerJ, DehlendorfC. Racial and ethnic disparities in contraceptive method choice in California. Perspect Sex Reprod Health, 2011; 43:173–180.
11.
JacobsJ, StanforsM. Racial and ethnic differences in U.S. women's choice of reversible contraceptives, 1995–2010. Perspect Sex Reprod Health, 2013; 45:139–147.
12.
DehlendorfC, ParkSY, EmeremniCA, ComerD, VincettK, BorreroS. Racial/ethnic disparities in contraceptive use: Variation by age and women's reproductive experiences. Am J Obstet Gynecol, 2014; 210:526.e1–529.e9.
13.
DehlendorfC, FosterDG, de BocanegraHT, BrindisC, BradsberryM, DarneyP. Race, ethnicity and differences in contraception among low-income women: Methods received by Family PACT Clients, California, 2001–2007. Perspect Sex Reprod Health, 2011; 43:181–187.
14.
MestadR, SecuraG, AllsworthJE, MaddenT, ZhaoQ, PeipertJF. Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. Contraception, 2011; 84:493–498.
RaineTR, Foster-RosalesA, UpadhyayUD, et al.One-year contraceptive continuation and pregnancy in adolescent girls and women initiating hormonal contraceptives. Obstet Gynecol, 2011; 117:363–371.
17.
PhillipsSJ, HoflerLG, ModestAM, HarveyLFB, WuLH, HackerMR. Continuation of copper and levonorgestrel intrauterine devices: A retrospective cohort study. Am J Obstet Gynecol, 2017; 217:57.e1–57.e6.
18.
MaslyanskayaS, CoupeySM, ChhabraR, KhanUI. Predictors of early discontinuation of effective contraception by teens at high risk of pregnancy. J Pediatr Adolesc Gynecol, 2015; 29:269–275.
19.
TrussellJ, VaughanB. Contraceptive failure, method-related discontinuation and resumption of use: Results from the 1995 National Survey of Family Growth. Fam Plann Perspect, 1999; 31:64–72, 93.
20.
StuartJE, SecuraGM, ZhaoQ, PittmanME, PeipertJF. Factors associated with 12-month discontinuation among contraceptive pill, patch, and ring users. Obstet Gynecol, 2013; 121:330–336.
21.
CastanoPM, BynumJY, AndresR, LaraM, WesthoffC. Effect of daily text messages on oral contraceptive continuation: A randomized controlled trial. Obstet Gynecol, 2012; 119:14–20.
22.
TuchmanLK, HuppertJS, HuangB, SlapGB. Adolescent use of the monthly contraceptive injection. J Pediatr Adolesc Gynecol, 2005; 18:255–260.
23.
GarbersS, Haines-StephanJ, LiptonY, MeserveA, SpielerL, ChiassonMA. Continuation of copper-containing intrauterine devices at 6 months. Contraception, 2013; 87:101–106.
24.
SecuraGM, AllsworthJE, MaddenT, MullersmanJL, PeipertJF. The Contraceptive CHOICE Project: Reducing barriers to long-acting reversible contraception. Am J Obstet Gynecol, 2010; 203:115.e1–115.e7.
25.
SpainJE, PeipertJF, MaddenT, AllsworthJE, SecuraGM. The Contraceptive CHOICE Project: Recruiting women at highest risk for unintended pregnancy and sexually transmitted infection. J Womens Health, 2010; 19:2233–2238.
26.
MaddenT, MullersmanJL, OmvigKJ, SecuraGM, PeipertJF. Structured contraceptive counseling provided by the Contraceptive CHOICE Project. Contraception, 2013; 88:243–249.
27.
DiedrichJT, ZhaoQ, MaddenT, SecuraGM, PeipertJF. Three-year continuation of reversible contraception. Am J Obstet Gynecol, 2015; 213:662.e1–662.e8.
28.
PeipertJF, ZhaoQ, AllsworthJE, et al.Continuation and satisfaction of reversible contraception. Obstet Gynecol, 2011; 117:1105–1113.
29.
RosenstockJR, PeipertJF, MaddenT, ZhaoQ, SecuraGM. Continuation of reversible contraception in teenagers and young women. Obstet Gynecol, 2012; 120:1298–1305.
30.
ClaytonDG, HillsM. Statistical models in epidemiology. Oxford, UK: Oxford University Press, 1993.
31.
SturmerT, RothmanKJ, AvornJ, GlynnRJ. Treatment effects in the presence of unmeasured confounding: Dealing with observations in the tails of the propensity score distribution—A simulation study. Am J Epidemiol, 2010; 172:843–854.
32.
ChowSC, ShaoJ, WangH. Sample size calculations in clinical research. New York, NY: Marcel Dekker, 2003.
33.
BehringerT, ReevesMF, RossiterB, ChenBA, SchwarzEB. Duration of use of a levonorgestrel IUS amongst nulliparous and adolescent women. Contraception, 2011; 84:e5–e10.
34.
LittlejohnKE. Hormonal contraceptive use and discontinuation because of dissatisfaction: Differences by race and education. Demography, 2012; 49:1433–1452.
35.
PolaneczkyM, LiblancM. Long-term depot medroxyprogesterone acetate (Depo-Provera) use in inner-city adolescents. J Adolesc Health, 1998; 23:81–88.
36.
HayfordSR, GuzzoKB. Racial and ethnic variation in unmarried young adults' motivation to avoid pregnancy. Perspect Sex Reprod Health, 2013; 45:41–51.
37.
CallegariLS, ZhaoX, SchwarzEB, RosenfeldE, MorMK, BorreroS. Racial/ethnic differences in contraceptive preferences, beliefs, and self-efficacy among women veterans. Am J Obstet Gynecol, 2017; 216:504.e1–504.e10.
38.
GuzzoKB, HayfordSR. Race-ethnic differences in sexual health knowledge. Race Soc Probl, 2012; 4:158–170.
39.
HopkinsB. Barriers to health care providers' provision of long-acting reversible contraception to adolescent and nulliparous young women. Nurs Womens Health, 2017; 21:122–128.
40.
MurphyMK, StoffelC, NolanM, HaiderS. Interdependent barriers to providing adolescents with long-acting reversible contraception: Qualitative insights from providers. J Pediatr Adolesc Gynecol, 2016; 29:436–442.
41.
GrindlayK, GrossmanD. Prescription birth control access among U.S. women at risk of unintended pregnancy. J Womens Health, 2016; 25:249–254.
42.
AndersonNB, BulataoRA, CohenB. Critical perspectives on racial and ethnic differences in health in late life. Washington, DC: The National Academies Press, 2004.
43.
LinkBG, PhelanJ. Social conditions as fundamental causes of disease. J Health Soc Behav, 1995;Spec No:80–94.
44.
KitturND, SecuraGM, PeipertJF, MaddenT, FinerLB, AllsworthJE. Comparison of contraceptive use between the Contraceptive CHOICE Project and state and national data. Contraception, 2011; 83:479–485.
